Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?

Surgical Oncology Clinics of North America

Volumn 25, Issue 4, 2016, Pages 861-872

  Canter, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Limb salvage; Multimodality therapy; Soft tissue sarcoma; Surgery; Survival

Indexed keywords

DOXORUBICIN; ERIBULIN; IFOSFAMIDE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOSENSITIVITY; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYXOSARCOMA; OVERALL SURVIVAL; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; SYNOVIAL SARCOMA; TREATMENT OUTCOME; UNDIFFERENTIATED PLEOMORPHIC SARCOMA; ADJUVANT CHEMOTHERAPY; ADULT; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY;

ADULT; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; SARCOMA;

EID: 84992612713     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2016.05.013     Document Type: Review

References (40)

1. 1 Canter, R.J., Surgical approach for soft tissue sarcoma: standard of care and future approaches. Curr Opin Oncol 27:4 (2015), 343–348.
2. 2 Demetri, G.D., Antonia, S., Benjamin, R.S., et al. Soft tissue sarcoma. J Natl Compr Canc Netw 8:6 (2010), 630–674.
3. 3 Gronchi, A., Colombo, C., Raut, C.P., Surgical management of localized soft tissue tumors. Cancer 120:17 (2014), 2638–2648.
4. 4 Kattan, M.W., Leung, D.H., Brennan, M.F., Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20:3 (2002), 791–796.
5. 5 Canter, R.J., Beal, S., Borys, D., et al. Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg 210:2 (2010), 191–198.e2.
6. 6 Reynoso, D., Subbiah, V., Trent, J.C., et al. Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol 101:4 (2010), 327–333.
7. 7 Wasif, N., Tamurian, R.M., Christensen, S., et al. Influence of specialty and clinical experience on treatment sequencing in the multimodal management of soft tissue extremity sarcoma. Ann Surg Oncol 19:2 (2012), 504–510.
8. 8 Sherman, K.L., Wayne, J.D., Chung, J., et al. Assessment of multimodality therapy use for extremity sarcoma in the United States. J Surg Oncol 109:5 (2014), 395–404.
9. 9 Biermann, J.S., Adkins, D.R., Agulnik, M., et al. Bone cancer. J Natl Compr Canc Netw 11:6 (2013), 688–723.
10. 10 Geller, D.S., Gorlick, R., Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8:10 (2010), 705–718.
11. 11 Mirabello, L., Troisi, R.J., Savage, S.A., Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:7 (2009), 1531–1543.
12. 12 Koohbanani, B., Han, G., Reed, D., et al. Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol 32:4 (2013), 246–252.
13. 13 Collins, M., Wilhelm, M., Conyers, R., et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 31:18 (2013), 2303–2312.
14. 14 Mariani, L., Miceli, R., Kattan, M.W., et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 103:2 (2005), 402–408.
15. 15 Eilber, F.C., Brennan, M.F., Eilber, F.R., et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 101:10 (2004), 2270–2275.
16. 16 Patrikidou, A., Domont, J., Cioffi, A., et al. Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol 12:1 (2011), 21–31.
17. 17 Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350:9092 (1997), 1647–1654.
18. 18 Roseman, M., Milette, K., Bero, L.A., et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 305:10 (2011), 1008–1017.
19. 19 Judson, I., Verweij, J., Gelderblom, H., et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15:4 (2014), 415–423.
20. 20 Frustaci, S., Gherlinzoni, F., De Paoli, A., et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19:5 (2001), 1238–1247.
21. 21 Frustaci, S., De Paoli, A., Bidoli, E., et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65:Suppl 2 (2003), 80–84.
22. 22 Cormier, J.N., Huang, X., Xing, Y., et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 22:22 (2004), 4567–4574.
23. 23 Petrioli, R., Coratti, A., Correale, P., et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 25:5 (2002), 468–473.
24. 24 Pervaiz, N., Colterjohn, N., Farrokhyar, F., et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113:3 (2008), 573–581.
25. 25 Woll, P.J., Reichardt, P., Le Cesne, A., et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 13:10 (2012), 1045–1054.
26. 26 Wasif, N., Smith, C.A., Tamurian, R.M., et al. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. JAMA Surg 148:7 (2013), 632–639.
27. 27 Gortzak, E., Azzarelli, A., Buesa, J., et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37:9 (2001), 1096–1103.
28. 28 Rosen, G., Forscher, C., Lowenbraun, S., et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73:10 (1994), 2506–2511.
29. 29 Eilber, F.C., Brennan, M.F., Eilber, F.R., et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 246:1 (2007), 105–113.
30. 30 Ferrari, A., De Salvo, G.L., Brennan, B., et al. Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol 26:3 (2015), 567–572.
31. 31 Canter, R.J., Qin, L.X., Maki, R.G., et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 14:24 (2008), 8191–8197.
32. 32 Dalal, K.M., Antonescu, C.R., Singer, S., Diagnosis and management of lipomatous tumors. J Surg Oncol 97:4 (2008), 298–313.
33. 33 Eilber, F.C., Eilber, F.R., Eckardt, J., et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 240:4 (2004), 686–695 [discussion: 695–7].
34. 34 Grobmyer, S.R., Maki, R.G., Demetri, G.D., et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 15:11 (2004), 1667–1672.
35. 35 Movva, S., von Mehren, M., Ross, E.A., et al. Patterns of chemotherapy administration in high-risk soft tissue sarcoma and impact on overall survival. J Natl Compr Canc Netw 13:11 (2015), 1366–1374.
36. 36 Yoon, S.S., Segal, N.H., Olshen, A.B., et al. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 15:8 (2004), 1261–1266.
37. 37 Yudoh, K., Kanamori, M., Ohmori, K., et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84:12 (2001), 1610–1615.
38. 38 Canter, R.J., Borys, D., Olusanya, A., et al. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 21:5 (2014), 1616–1623.
39. 39 Jakob, J., Simeonova, A., Kasper, B., et al. Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma. Ann Surg Oncol 22:9 (2015), 2839–2845.
40. 40 Gronchi, A., Bui, B.N., Bonvalot, S., et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 23:3 (2012), 771–776.